Estrogen regulates the growth and differentiation of the uterus via binding to estrogen receptors (ERs), members of the nuclear receptor family of transcription factors. Two forms of ER exist: ER␣ and ER␤. The former is a well-characterized mediator of estrogen-induced transcription, but the function of the latter is unclear. Recent in vitro studies suggest that both splicing forms of ER␤ expressed in rat tissues, ␤1 and ␤2, may function as inhibitors of ER␣ transcriptional activity. To gain insight into the role of ER␤ in estrogen action, we examined the effects of estrogen and relaxin, a ligand-independent activator of ERs, on the expression of ER␤1 and ER␤2 mRNA in the uterus in vivo. Eighteen-day-old female rats were ovariectomized and, after recovery, treated with 17␤-estradiol, relaxin, or vehicle. Quantitative reverse transcription-polymerase chain reaction analyses of uterine RNA from estrogen-treated animals revealed marked decreases in the steady-state levels of the mRNAs for both ER␤1 and ER␤2 at 3, 6, and 24 h after treatment. Relaxin induced a similar effect. Neither hormone had any significant effect on ER␣ mRNA levels. To determine if endogenous estrogen exerts this effect, we examined the expression of ER␤s in the uterus during the estrous cycle. Levels of both isoforms were highest at diestrus (low estrogen), were significantly lower at early proestrus (rising estrogen), reached a nadir during late proestrus (peak estrogen), and rebounded at estrus (declining estrogen). These data suggest that down-regulation of ER␤ expression may be required for estrogen to exert its full trophic effects on the uterus.
INTRODUCTION
The diverse effects of estrogen on a wide range of target tissues are mediated by estrogen receptors (ERs), nuclear transcription factors that are activated either upon binding of estrogen and estrogen-like ligands or via cross-talk, most likely through phosphorylation of the unliganded receptors, with various other signal transduction pathways [1] [2] [3] [4] . Recently, a second form of ER, designated ER␤ to differen- tiate it from the original ER (consequently called ER␣), was discovered [5] [6] [7] . A further layer of complexity was added when a second common splicing variant of ER␤ was identified in tissues of both the rat and mouse [8] [9] [10] [11] [12] . Designated ER␤2 (with the original form becoming ER␤1), it contains a 54-base pair (bp)/18-aa insert within the ligandbinding domain.
The physiological function of ER␤ is presently unclear, but its discovery has necessitated a complete reevaluation of estrogen signaling pathways in target cells. The cyclic growth and differentiation of the uterine endometrium and other tissues of the reproductive tract are controlled in large part by estrogen [2, 4, 13] . While the predominant ER in the uterus is ER␣, numerous investigators have reported that ER␤ is also expressed there, albeit at a markedly lower level [14] [15] [16] [17] [18] [19] [20] . ER␤2, the longer splice variant present in rodents, has been reported to coexist with ER␣ and ER␤1 in all tissues examined, including the uterus, prostate, and ovary [10] , and the level of its expression is similar to, in some cases greater than, that of ER␤1 [8, 9] . ER␤ protein has also been detected in the rodent uterus by immunohistochemistry [19, 20] . Thus, a substantial body of evidence indicates that both ER␤ mRNA and protein are expressed in the uterus.
With regard to function, it has been repeatedly demonstrated in transfection studies that ER␤1 is capable of mediating estrogen-induced reporter gene transcription in vitro, but it is significantly less active than ER␣ [7, 21] . Furthermore, it remains to be definitively shown that endogenous ER␤1 acts as a transcriptional activator of endogenous genes at physiological estrogen concentrations in vivo. ER␤2 binds estrogen with still lower affinity than ER␤1 and is a much weaker inducer of transcriptional activity [10] [11] [12] . On the other hand, there is mounting evidence, also from in vitro transfection studies, that both isoforms of ER␤ could actually serve to inhibit ER␣ signaling in target tissues [10, 12, 21] . ER␤2 was first shown to inhibit estrogen-dependent, ER␣-mediated expression of estrogen response element (ERE)-containing reporter genes in COS-1 cells [10] . Subsequently, Hall and McDonnell [21] demonstrated that human ER␤ (homologous to rat/mouse ER␤1) also repressed ER␣ activity in HepG2 cells in response to subsaturating concentrations of 17␤-estradiol, which is physiologically relevant because estrogen's uterotrophic effects require only 5-20% receptor occupancy [13] . The inhibitory effect of ER␤s could involve formation of heterodimers with ER␣ [11, 12, [21] [22] [23] , an interaction that is enhanced by estrogen [11, 21] . In addition, ER␤1, unlike ER␣, appears to interact with the ERE in the absence of ligand [21] , suggesting that it may also competitively inhibit ER␣ binding to DNA. Such interactions would, of course, require that ER␣ and ER␤ be coexpressed in cells. Several studies indicate that both are expressed in uterine epithelial and stromal cells [16, 17, 19, 20, 24, 25] . That ER␤s normally oppose estrogen's uterotrophic actions in vivo can also be inferred from the recent observation that ER␤ knock-out (␤ERKO) mice show exaggerated uterine responsiveness to estrogen, such as greater edema and increased rates of cell proliferation [24] . This hypersensitivity may be detrimental to uterine function because ␤ERKO females that become pregnant are reported to exhibit an abnormally high incidence of fetal death [7, 24] .
Resolving the question of ER␤'s physiological roles will depend in part on defining where and when the various ER subtypes are expressed relative to each other and how their expression is regulated in vivo. There is relatively little known about the regulation of ER␤ expression in target tissues at this time. In the ovary, ER␤ is down-regulated by gonadotropin treatment [26] , while estrogen has been reported to reduce ER␤ expression in some areas of the brain and in the pituitary [27] [28] [29] . In contrast with the latter findings, it was recently reported that estrogen has no effect on ER␤ expression in the uterus at 24 h [30] . In the present study, we examined the effects of estrogen and relaxin, a peptide hormone that activates ERs independently of ligand [31] , on the expression of both ER␤1 and ER␤2 at earlier time points. Furthermore, we determined their pattern of expression during the normal estrous cycle.
MATERIALS AND METHODS

Animals and Experimental Design
Animal studies were conducted in accordance with mandated standards of humane care as described in the Guide for the Care and Use of Laboratory Animals (National Research Council) and approved by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine.
To examine the effect of estrogen on ER␤1, ER␤2, ER␣, and VEGF (vascular endothelial growth factor) expression in the uterus, female Sprague-Dawley rats (Crl:CD[SD] BR strain; Charles River, Wilmington, MA) were ovariectomized at 18 days of age and allowed to recover for 7-10 days. For each experiment, animals were randomly divided into treatment groups. Treatments were administered as single i.p. injections. For the majority of the experiments, rats were treated with 17␤-estradiol (Sigma Chemical Co., St. Louis, MO), 50 ng/g body weight (BW) in 200-l vehicle (ethanol:PBS, 1:500), or vehicle alone. At 3 and 6 h or 6 and 24 h following injection, animals from each treatment group were killed by cervical dislocation and uteri were removed for RNA extraction (below). In an additional experiment, the effects of different doses of 17␤-estradiol (0, 0.5, 5, and 50 ng/g BW) were compared at 6 h.
To compare the effect of relaxin, a ligand-independent activator of ERs, with that of estrogen, animals were treated with either 17␤-estradiol (50 ng/g BW), purified porcine relaxin (0.85 g/g BW in 200 l PBS; [32] ), or vehicle alone. Animals were killed 6 h later and their uteri collected.
To examine the regulation of ER␤1 and ER␤2 expression in the ovary by gonadotropins, intact, 27-day-old female Sprague-Dawley rats were separated into four groups (three animals per group). Group 1 (controls) received a single injection (i.p.) of PBS vehicle. Groups 2-4 received single injections of eCG (8 IU/200 l PBS/animal; National Hormone and Pituitary Program, NIDDK). Forty-eight hours following eCG treatment, animals in groups 3 and 4 received a single i.p. injection of hCG (5 IU/ 200 l PBS/animal; Sigma), while animals in group 2 were killed by cervical dislocation and the ovaries removed. Six hours following hCG injection (preovulation), animals in group 3 were killed, followed at 20 h (postovulation) by animals in groups 1 and 4.
To measure uterine ER␤ mRNAs during the normal estrous cycle, intact 8-to 10-wk-old female Sprague-Dawley rats were used. To monitor cycles, vaginal cytology was examined daily. Only animals exhibiting two consecutive normal estrous cycles were used. Animals were killed and uteri collected either between 1000 and 1100 (early proestrus, estrus, or diestrus) or at 1700 (late proestrus) h.
RNA Extraction
In all experiments, uteri were dissected out immediately after rats were killed, trimmed to remove extraneous tissue, flash frozen in liquid nitrogen, and stored at Ϫ80ЊC for subsequent RNA extraction. Total RNA was extracted using the RNeasy RNA extraction kit (Qiagen, Inc., Valencia, CA). Tissues were first homogenized in buffer RLT using a bead mill (Mini Beadbeater; Biospec Products, Bartlesville, OK) and 1 mm zirconium silicate beads (30 sec at 5000 rpm). Homogenates were then sheared three times by passage through a 23-gauge needle. All subsequent purification steps were carried out according to the manufacturer's instructions. The concentration and purity of the RNA in each sample were determined by measurement of absorbance at 260 and 280 nm. The concentration of total RNA was then normalized for all samples to 1 g/6 l of water for reverse transcription (RT).
Reverse Transcription-Polymerase Chain Reaction
Relative levels of specific mRNAs/g of total RNA were compared among treatment groups using quantitative reverse transcription-polymerase chain reaction (RT-PCR). This method, with modifications (described below), has been used previously for the comparison of relative levels of VEGF mRNA in the uterus after estrogen treatment [33] and in the ovary after gonadotropin stimulation [34] . This assay has been demonstrated to accurately measure the relative difference in specific mRNA concentration in standard solutions prepared by dilution [33, 34] and yields results similar to those obtained by Northern analysis [35, 36] . In the present study, relative levels of target mRNA PCR product in samples from each treatment group, amplified beginning with equal amounts of total RNA and under identical conditions (after determining the number of cycles for optimal exponential amplification for each target mRNA), were compared based on optical density of product bands rather than by comparing the extinction point of serially diluted samples. The accuracy of the densitometric analysis was validated using serial dilutions of a standard cDNA (i.e., a twofold difference in the amount of cDNA loaded on a gel yielded a twofold difference in optical density). To confirm that total RNA measurements were accurate and that approximately equal amounts of total RNA had been reverse transcribed, within each experiment, 18S ribosomal (r) RNA levels in samples from representative experiments were compared. 18S rRNA has been shown to be the least variable of several commonly used housekeeping genes [37] . There were no significant differences in the yield of 18S rRNA RT-PCR product from equal amounts of uterine total RNA among experimental groups, either when comparing uteri from control and estrogen-treated immature ovx females (P Ͼ 0.2 to 0.7) or from adult cycling females (P Ͼ 0.3 to 0.9). Normalization of target transcript levels to 18S rRNA levels had no effect on the results and, therefore, the results normalized to total RNA alone are shown. Further validation of this approach was the demonstration that the effects of estrogen on uterine VEGF mRNA levels (see Fig. 4 ) yielded results similar to those reported by us previously [33] as well as by others using Northern analysis [35] .
Total RNA (1 g/6 l of water) was reverse-transcribed [33, 34] by incubation at 37ЊC for 60 min with the following reagents (from Life Technologies, Gaithersburg, MD, unless otherwise indicated): 1) 200 U (1 l) cloned Moloney murine leukemia virus reverse transcriptase; 2) 5ϫ reaction buffer (250 mM Tris-HCl [pH 8.3], 375 mM KCl, and 15 mM MgCl 2 ), 4 l; 3) bovine serum albumin (Boehringer Mannheim, Indianapolis, IN), 0.1% (wt/vol), 2 l; 4) 100 mM dithiothreitol, 2 l; 5) dNTPs (2.5 mM each of dATP, dCTP, dGTP, and dTTP), 4 l; and 6) random primer oligodeoxyribonucleotides (500 ng/l), 1 l. Reverse transcribed samples were then placed on ice or frozen until used for PCR. For each RT run, a reagent blank was prepared in which an equal volume of water was substituted for RNA sample.
Oligonucleotide primers for PCR were synthesized by Life Technologies. Primers for each product were as follows, with the location of each primer in the target transcript (based on GenBank sequences) indicated in parentheses: rat cDNAs (GenBank accession numbers: Y00102 for ER␣, AF042059 for ER␤, AF215725 for VEGF, and X01117 K01593 for 18S rRNA). The ER␣, ER␤1/␤2, and VEGF primer pairs all span at least one intron. For the other pairs, the possibility of amplification from genomic DNA was eliminated by pretreatment of the RNA with DNase (RNeasy RNA extraction kit, Qiagen). The ER␤ primer pair was located upstream of the alternative splice site and therefore did not differentiate between ER␤1 and ER␤2 (Fig. 1A) ; they yielded a single PCR product of 251 bp. The ER␤1/␤2 primers [10] span the splicing site and yield two PCR productsone for each splicing form (246 and 300 bp for ER␤1 and ER␤2, respectively). The ER␤2 primers, one of which was located within the 54-bp insert, recognize only that splicing form (yielding a 174-bp product). PCR was performed as described previously [33, 34] . PCR incubations were carried out in a programmable thermal cycler (MJ Research, Cambridge, MA). A reagent blank prepared using the RT blank was included in all PCR runs. Following PCR, 8-l aliquots of each sample were mixed with 2 l of 5ϫ loading buffer (30% Ficoll, 0.2 M EDTA, 0.25% bromphenol blue, and 0.25% xylene cyanole FF). These were fractionated by electrophoresis on 10 ϫ 10-cm, 0.8-mm-thick, nondenaturing, 8% polyacrylamide gels at a constant 70 V. Double-stranded DNA standards were also run on each gel (50-bp DNA ladder; Life Technologies). Following fractionation, gels were stained for 30 min with ethidium bromide (0.5 g/ml in distilled water; Sigma), destained for 15 min in distilled water, and examined on a 312-nm ultraviolet transilluminator. Gels were photographed as described previously [33] .
Each cycle of PCR consisted of 1 min at 94ЊC, 0.5 min at 60ЊC, 1.5 min at 72ЊC, and a final extension of 5 min at 72ЊC. The optimal number of PCR cycles (the number of cycles yielding a readily detectable product but still within the linear range of amplification) was first determined for each target mRNA. The numbers of cycles were 20-22 for ER␣, 28-30 for ER␤1/␤2, and 26-28 for VEGF.
Restriction Enzyme Analysis
Restriction enzyme analysis was used to verify the identity of PCR products. Restriction sites present in the amplified regions were mapped using the Baylor College of Medicine Search Launcher Sequence Utility (mbcr.bcm.tmc.edu/services.html). Digestions were carried out per manufacturer's instructions.
Densitometry and Statistical Analysis
The densities of gel bands for RT-PCR products were quantified by analyzing the film negatives using a Polaroid Digital Microscope Camera fitted with a Nikon AF Micro Nikkor 60-mm lens and Quantiscan for Windows (version 2.1; Biosoft, Inc., Ferguson, MO). Relative optical densities are expressed in arbitrary units. The data were analyzed using oneway ANOVA followed by the Fisher protected least significant difference test (StatView for Windows, Version 4.57; Abacus Concepts, Inc., Berkeley, CA). PCR product bands shown in the figures are taken from the photographic negatives and therefore are reverse images.
RESULTS
Detection of ER␣ and ER␤ mRNAs in the Rat Uterus by RT-PCR
An abundant ER␣ PCR product of the expected size (419 bp) was generated after just 20-22 cycles from reverse transcribed uterine mRNA from immature ovx rats (Fig.  1B) . The identity of this product was confirmed by restriction enzyme analysis (data not shown). Although there have been a few reports that ER␤ is not expressed in the rodent uterus, numerous other studies have shown that ER␤ transcripts are present in this organ, although at lower levels than ER␣ mRNA [8, 10, 11, 14-16, 24, 25] . Consistent with this, ER␤ primers located upstream of the alternative splice site in the ER␤ sequence (primers 5ЈP1 and 3ЈP1; Fig. 1A ) generated a single PCR product of the expected 251-bp size from uterine RNA after 28-30 PCR cycles (Fig. 1B) . When primers that span the alternative splice site in the ER␤ gene (5ЈP2 and 3ЈP2; Fig. 1A) were used, two product bands were generated (Fig. 1B) . Their sizes closely matched the 246-and 300-bp products expected for ER␤1 and ER␤2, respectively, with the difference corresponding to the 54-bp insertion in the ligand-binding domain of ER␤2 [8] [9] [10] [11] . Restriction enzyme analysis confirmed the identity of both the common ER␤ product and the products for the ␤1 and ␤2 splicing forms (data not shown). In agreement with previous reports that levels of ER␤1 and ER␤2 transcripts are often roughly equivalent [8] [9] [10] [11] , the yield of the two ER␤ splicing products was similar, with that for ER␤1 being slightly more abundant. To further confirm that the larger product was that for ER␤2, an antisense primer located within the 54-bp insert unique to that transcript was made (3ЈP3; Fig. 1A ). Its use with primer 5ЈP2 resulted in a single PCR product of the expected size (174 bp ; Fig.  1B) ; its identity was also confirmed by restriction enzyme analysis (data not shown). Thus, although ER␣ mRNA was more abundant in the rat uterus, transcripts for both splicing forms of ER␤ were also readily detectable.
Effect of Estrogen on ER␣ and ER␤ Expression in the Rat Uterus
It was recently reported that estrogen treatment of immature ovx rats has no effect on ER␤ mRNA levels in the uterus [30] . However, that study did not look at expression until 24 h after estrogen treatment, although estrogen exerts direct effects on the expression of genes in the uterus within minutes to a few hours [33, 36] . In the present study, we examined the effects of estrogen treatment on ER␤ mRNA levels at much earlier time points. As shown in Figure 2A , 17␤-estradiol (50 ng/g BW) caused a significant reduction in the levels of both ER␤1 and ER␤2 PCR products generated from uterine RNA at both 3 and 6 h (by approximately 42% and 82% at 6 h, respectively). Thus, there is a rapid reduction in steady-state levels of ER␤1 and ER␤2 mRNAs in the uterus following estrogen treatment.
To determine if ER␤ levels rebound after this initial down-regulation, which might explain why Wang et al. [30] saw no down-regulation at 24 h, an experiment was carried out in which uteri were collected at 6 and 24 h post-estrogen treatment. As shown in Figure 2C , however, both, ER␤1 and ER␤2 levels were strongly depressed at both time points; the effect on ER␤1 levels was even greater than in the first experiment, nearly matching the decrease in ER␤2 levels.
In contrast with the effect of estrogen on ER␤1 and ER␤2, ER␣ mRNA levels were unaffected by estrogen at 3, 6, or 24 h (Fig. 2, B and D) .
In a third independent experiment, a 10-fold lower dose of 17␤-estradiol, 5 ng/g BW, was nearly as effective as 50 ng in reducing the yield of ER␤1 and ER␤2 RT-PCR products (Ϫ62% and Ϫ72% versus Ϫ71% and Ϫ80%, respectively; n ϭ 3 per group; P Ͼ 0.1) compared with controls (n ϭ 4; P Ͻ 0.05 for either dose) at 6 h. Again, there was no significant change in the level of ER␣ mRNA in response to either dose of 17␤-estradiol at this time point.
Effect of Estrogen on VEGF Expression in the Rat Uterus
We have previously reported that estrogen rapidly upregulates VEGF expression in the rat uterus [33] . The yield of PCR products for VEGF 164 and VEGF 120 , the two predominant alternatively spliced VEGF transcripts in the uterus [33] , from uterine RNA samples were strongly stimulated by estrogen at the same time points at which levels of ER␤ mRNAs were depressed (Fig. 3) . Thus, the inhibitory effect of estrogen on ER␤ mRNA levels was specific and occurred at the same time that the levels of other estrogen-induced mRNAs were increasing.
Effect of Relaxin on ER␣ and ER␤ Expression in the Rat Uterus
The peptide hormone relaxin, which exerts acute trophic effects on the uterus similar to those induced by estrogen, Equal amounts of total RNA were reverse transcribed and amplified as described in Materials and Methods. *P Ͻ 0.05; §P Ͻ 0.001 versus respective control value.
FIG. 6. Relative levels of ER␤1, ER␤2, and ER␣ transcripts in the uterus during the normal estrous cycle. Mature, cycling female rats were killed at the stages indicated and total RNA was isolated from uteri. Equal amounts of total RNA were analyzed by RT-PCR as described in Materials and Methods. A total of 9 (early proestrus, late proestrus, and diestrus) or 10 (estrus) rats are represented in each group. Relative optical density values were normalized either to the ER␤1 mean at diestrus (top) or the ER␣ mean at diestrus (bottom). *P Ͻ 0.0001 versus ER␤1 at diestrus; §P Ͻ 0.05 versus ER␤2 at diestrus; #P Ͻ 0.005 versus ER␣ at all other stages.
FIG. 5.
Relative levels of ER␤ transcripts in the ovary after gonadotropin treatment. RNA was extracted from ovaries of immature rats (three per treatment group) following treatment with vehicle alone (C), eCG (PMSG in figure) (8 IU) for 48 h, eCG for 48 h plus hCG (5 IU) for an additional 6 h, or eCG for 48 h plus hCG for an additional 20 h. Equal amounts of total RNA were reverse transcribed and amplified using the common ER␤ primer pair (yielding a single 300-bp product), as described in Materials and Methods. *P Ͻ 0.05 versus control value.
does so in part through ligand-independent activation of ERs [31] . We asked, therefore, whether relaxin would also down-regulate uterine ER␤ levels. As shown in Figure 4 , relaxin, like estrogen, caused a marked decrease in the steady-state levels of ER␤1 and ER␤2 mRNA at 6 h. The effect of relaxin was somewhat less than that of estrogen in the same experiment. This is consistent with our previous observation that the early uterotrophic effects of relaxin are somewhat weaker than those induced by estrogen [31] .
Effect of hCG on ER␤ Expression in the Rat Ovary
It has been reported that LH or hCG rapidly down-regulate ER␤ expression in the rat ovary [26] . To determine if we could detect the same effect and to compare it with the effect of estrogen on uterine ER␤ levels, we examined ovaries from eCG-primed, immature animals after hCG treatment. As shown in Figure 5 , hCG caused a significant decrease in ovarian ER␤ levels (to 60% of control) at 20 h. The magnitude of this effect was similar to that reported by Byers et al. [26] , although it occurred later than in that study, which saw a marked decrease at 6 h after hCG.
Expression of ER␤ mRNA in the Rat Uterus During the Estrous Cycle
During the rat estrous cycle, serum 17␤-estradiol levels rise slowly during diestrus, increase rapidly to a peak during proestrus, and decline sharply to a nadir during estrus [38] . Based on the studies in immature animals, we hypothesized that ER␤ levels would be lowest during proestrus. Therefore, we examined the pattern of expression of ER␤s in the uteri of adult rats at each stage of the estrous cycle. As in the immature ovx animals, both isoforms of ER␤ were readily detectable in the adult uterus at all stages of the cycle (Fig. 6, top) . Levels of both isoforms were highest at diestrus, significantly lower at early proestrus, lowest at late proestrus (ER␤1 22% and ER␤2 24% of diestrus values; P Ͻ 0.05), and increased again at estrus. Thus, the increase in endogenous 17␤-estradiol at proestrus rapidly inhibits the expression of both ER␤1 and ER␤2 in the uterus, similar to the effect of exogenous 17␤-estradiol in immature ovx rats. Furthermore, these results indicate that ER␤ expression rebounds rapidly after estrogen levels decline during the estrous cycle; this differs from the situation observed in immature ovx mice treated with a high level of exogenous 17␤-estradiol.
ER␣ mRNA levels during the cycle were less variable than those for ER␤. Levels were highest during diestrus and early proestrus, fell by just over 40% during late proestrus (P Ͻ 0.05 compared with early proestrus), and increased again to near maximal levels during estrus (Fig. 6,  bottom) .
DISCUSSION
These studies show that the expression of ER␣ and ER␤ are differentially regulated by estrogen in the rat uterus, further evidence that these two molecules play different roles there. Treatment of immature ovx rats with 17␤-estradiol rapidly down-regulated both ER␤1 and ER␤2 transcripts while leaving that for ER␣ unchanged. This effect was also induced by relaxin, a ligand-independent activator of ERs [31] , indicating that down-regulation does not require ligand per se but only activation of ERs (presumably ER␣). The physiological relevance of this rapid down-regulation is indicated by the fact that it also occurs during the normal estrous cycle: ER␤ mRNA levels decrease between early and late proestrus, when estrogen levels peak [38] . In the immature ovx rat, the inhibitory effect of estrogen was sustained for at least 24 h. During the cycle, however, ER␤ expression rapidly rebounded after proestrus. This difference most likely is due to a more sustained period of elevated estrogen in the immature ovx model. The decline in whole uterus probably represents the net result of greater and lesser changes in different uterine cell populations. This is supported by the observation that a decline in uterine ER␤ after 72 h of estrogen treatment occurred primarily in stromal cells [24] . This spatially links lower ER␤ expression and estrogen action because estrogen-induced epithelial cell proliferation is mediated by ERs in stromal cells, not those in the epithelial cells themselves [39] . The rapid decline in ER␤ mRNAs could result from decreased transcription, increased degradation, or both.
A possible implication of these results is that a reduction in ER␤ levels may be necessary for estrogen and other ER activators to exert their full trophic effect on the uterus. This assumes that a decrease in ER␤ mRNA is followed by a decline in protein. While quantitating low levels of ER␤ protein remains problematic, a limited number of studies support such a relationship [24, 40] . This pattern fits well with the mounting evidence that ER␤s may negatively modulate ER␣ transcriptional activity [10, 21, 41] . The rapid decrease in ER␤ mRNA levels precedes estrogen's late uterotrophic effects, such as increased DNA synthesis and cell proliferation, which occur only after 7-8 h of tight binding of hormone-ER complexes to nuclear sites [13, 42] , a period during which ER␤ protein levels might likewise decline. Why this extended period of receptor association is necessary has never been explained. Our results suggest a possible explanation: the need to first down-regulate levels of ER␤. Variation in the degree to which different genes are inhibited by ER␤ and the regulation of ER␤ levels by estrogen may be key mechanisms through which estrogen is able to progressively induce the expression of different genes over an extended period of time. Early response genes, such as VEGF [33] , may be less subject to this inhibitory effect than those that are required later for DNA synthesis and endometrial hyperplasia.
The lower level of ER␤ expression in the uterus relative to that in the ovary or to that of ER␣ in the uterus has led some to conclude that it could not play a significant role there. As a receptor as well as a transcription factor, ER␣ levels in target cells must be high to enable the efficient detection of changes in estrogen concentration. If ER␤ plays different roles than ER␣, including some not dependent on ligand binding [21] , the level of expression of the two genes or the concentration of the two proteins need not be similar. The relevant comparison may be between levels of ER␤ and liganded ER␣, a small fraction of total ER␣ at physiological estrogen concentrations [13] .
Based on our observations and numerous published studies, quantitative RT-PCR is the only method with sufficient sensitivity to reliably detect ER␤ expression in the rodent uterus and to quantitatively show a further reduction in levels following estrogen treatment. We chose to normalize expression to total RNA rather than a housekeeping gene because numerous studies have demonstrated that few, if any, such genes remain constant in cells or tissues undergoing rapid growth or remodeling in response to stimuli. One recent study found that even the least variable of these, 18S ribosomal RNA, still required normalization to total RNA before it could be used as a standard for normalization of other genes [37] . We confirmed this by measuring 18S rRNA in representative samples and found that the levels of this housekeeping gene did not differ significantly between experimental groups. Our previous studies and validation steps led us to a similar conclusion: RT-PCR product yield from equal amounts of total RNA under identical conditions and cycle number in the linear range of amplification is an accurate reflection of the relative amounts of target mRNA in the starting samples. This approach does not control for intraassay variation due to such things as pipeting error or slight differences in the efficiency of the reverse transcription or polymerization reactions. Because internal housekeeping genes are amplified in separate reactions and so are subject to the same random variables, normalizing to them also does not correct for such variability. Instead, we show the variability between replicates (the SEM), the major component of which is likely normal interanimal variation. As can be seen, the variation was modest and did not mask the differences resulting from estrogen treatment, which were highly reproducible and statistically significant. Finally, it should be remembered that, in the same samples in which ER␤ levels sharply declined, VEGF mRNA levels increased severalfold and ER␣ mRNA levels were constant.
In contrast with our results, Wang et al. [30] reported that ER␤ mRNA levels in uteri of ovx adult rats were unaffected by 17␤-estradiol 24 h after treatment nor did they observe any significant change in levels during the estrous cycle [43] . Ovariectomy itself is reported to cause a marked decrease in ER␤ expression in the adult rat uterus [16] , however, so a further decline in response to estrogen might not be observed. In agreement with our findings, Weihua et al. [24] found that daily injection of 17␤-estradiol for 3 days decreased both ER␤ mRNA and protein levels in the immature, intact mouse uterus; the magnitude of the change, however, was not quantitated. ER␣ mRNA levels appeared to be somewhat higher than controls at the same time point. The authors speculated that the activity of ER␣ may be suppressed by ER␤ during the prepubertal period but that estrogen secretion at puberty inhibits ER␤ expression, thereby making ER␣ fully functional. We propose that this effect of ER␤ does not end at puberty but becomes cyclic with the level of ER␤ and the degree of suppression, varying inversely with estrogen levels (although some estrogen is apparently also required to maintain ER␤ expression [16] ).
Estrogen down-regulation of ER␤ mRNA has also been observed in the brain, although these studies involved longer periods (1-2 wk) of treatment [27, 28] . ER␤ mRNA levels also decline in the pituitaries of a) ovx rats after treatment with estrogen for 3 days [29] , b) intact female rats at puberty [44] , and c) intact adult female rats during proestrus [29] . ER␤ expression also decreases in GnRH neurons in the hypothalamus at proestrus [45] . Most recently, estrogen (for 8 days) was shown to strongly inhibit ER␤ mRNA levels in mouse mesenchymal stem cells while at the same time up-regulating ER␣ expression [46] .
Similar to the effects of estrogen in the uterus, gonadotropin treatment rapidly down-regulates ER␤ mRNA [26] and protein [40] in the ovary. This might be due to rising estrogen levels. Consistent with this, treatment of immature rats with diethylstilbestrol for either 24 or 96 h also lowered granulosa cell ER␤ mRNA levels [47] and ER␤ mRNA in sheep granulosa cells varied inversely with estradiol production [48] . Studies of the ␤ERKO mouse indicate that ER␤ is essential for normal follicular development and function [4] . We propose that this may be because it protects ovarian cells from the effects of estrogen levels orders of magnitude higher than those to which peripheral tissues are exposed. Interestingly, ovarian ER␣ transcripts did not change during the estrous cycle [26] , similar to what we observe in the uterus.
In contrast with its effects on ER␤, estrogen had little effect on ER␣ mRNA levels in uteri of immature ovx rats. Only one other similar study has been done using this model [49] . As here, there was no difference in ER␣ levels at 6 h, but there was a significant increase at 24 h, which we did not observe. The dose of estrogen, the route of administration, and the method of mRNA quantitation, however, differed between the two studies. Studies in adult ovx rats are complicated by the fact that ovariectomy itself causes an increase in uterine ER␣ mRNA levels [16, 50, 51] . In one such study, estrogen further stimulated ER␣ mRNA expression [50] but in another strongly repressed it [51] . Such differences may result from the fact that estrogen also stimulates the expression of many commonly used housekeeping genes, such as ␤-actin, in the uterus [50, 52] and normalizing to such transcripts distorts results. Previous studies of ER␣ expression in the uterus of the rat during the estrous cycle are also difficult to interpret. One group has reported highest levels at proestrus and a significantly lower level at metestrus [52, 53] , but the magnitude of difference between the high and low points was substantially different in those two studies. They also did not examine late proestrus, and we did not look during metestrus.
In summary, these studies show that both estrogen and relaxin rapidly down-regulate ER␤ expression. We propose that this may be a requisite event for estrogen and other ER activators to exert their normal uterotrophic effects because ER␤s may function in part as inhibitors of ER␣-mediated transcriptional activity. Because overstimulation of cell proliferation by estrogens is believed to contribute to the development of cancer in target tissues, inhibition of ER␤ expression by estrogen may contribute to that process [54] . Several recent studies have found that expression of ER␤ is lower in cancers compared with healthy tissues [55] [56] [57] .
